PMID- 15814334
OWN - NLM
STAT- MEDLINE
DCOM- 20050616
LR  - 20181113
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 81
IP  - 3
DP  - 2005 Apr
TI  - Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in 
      chronic-phase chronic myeloid leukemia patients during the primary stage of 
      imatinib mesylate therapy.
PG  - 235-41
AB  - We describe a method for monitoring chronic myeloid leukemia (CML) patients 
      treated with imatinib that uses fluorescence in situ hybridization (FISH) to 
      detect BCR-ABL in peripheral blood (PB) granulocytes. First, we compared this 
      method, termed Neutrophil-FISH, with interphase FISH (i-FISH) analysis of bone 
      marrow (BM), i-FISH analysis of PB mononuclear cells, and conventional 
      cytogenetic analysis (CCA) of BM in 30 consecutive CML patients. We found the 
      percentage of BCR-ABL-positive neutrophils as determined by Neutrophil-FISH to 
      correlate best with the percentage of Philadelphia chromosome-positive metaphases 
      in the BM determined by CCA (y = 0.8818x + 5.7249; r(2) = 0.968). We then 
      performed a serial Neutrophil-FISH study of 10 chronic-phase CML patients treated 
      with imatinib and found that the technique could clearly separate imatinib 
      responders from nonresponders within 12 weeks of drug administration. There was a 
      significant difference in the percentages of BCR-ABL-positive neutrophils between 
      responder (mean 3 SD, 18.2% 3 11.8%) and nonresponder (82.4% 3 5.1%) groups at 12 
      weeks (P < .0001, Student t test).Together with real-time quantitative polymerase 
      chain reaction analysis, Neutrophil-FISH represents another useful method for 
      monitoring CML patients during the primary myelosuppressive stage of imatinib 
      therapy because it is a quick, simple, and reliable method for assessing 
      cytogenetic response.
FAU - Takahashi, Naoto
AU  - Takahashi N
AD  - University of Saskatchewan, College of Medicine, Pathology Department and 
      Saskatchewan Cancer Centre, Saskatoon, Canada.
FAU - Miura, Ikuo
AU  - Miura I
FAU - Kobayashi, Yoshimi
AU  - Kobayashi Y
FAU - Kume, Masaaki
AU  - Kume M
FAU - Yoshioka, Tomoko
AU  - Yoshioka T
FAU - Otane, Wataru
AU  - Otane W
FAU - Ohtsubo, Kaori
AU  - Ohtsubo K
FAU - Takahashi, Kaoru
AU  - Takahashi K
FAU - Kitabayashi, Atsushi
AU  - Kitabayashi A
FAU - Kawabata, Yoshinari
AU  - Kawabata Y
FAU - Hirokawa, Makoto
AU  - Hirokawa M
FAU - Nishijima, Hirokazu
AU  - Nishijima H
FAU - Ichinohasama, Ryo
AU  - Ichinohasama R
FAU - Decoteau, John
AU  - Decoteau J
FAU - Miura, Akira B
AU  - Miura AB
FAU - Sawada, Ken-Ichi
AU  - Sawada K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Benzamides
MH  - Female
MH  - Fusion Proteins, bcr-abl/*biosynthesis
MH  - Humans
MH  - Imatinib Mesylate
MH  - *In Situ Hybridization/methods
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/pathology/physiopathology
MH  - Leukemia, Myeloid, Chronic-Phase/drug therapy/pathology/*physiopathology
MH  - Male
MH  - Monitoring, Physiologic/methods
MH  - Neutrophils/*metabolism/pathology
MH  - Piperazines/*administration & dosage
MH  - Pyrimidines/*administration & dosage
EDAT- 2005/04/09 09:00
MHDA- 2005/06/17 09:00
CRDT- 2005/04/09 09:00
PHST- 2005/04/09 09:00 [pubmed]
PHST- 2005/06/17 09:00 [medline]
PHST- 2005/04/09 09:00 [entrez]
AID - JBG6VGJXWGN621L7 [pii]
AID - 10.1532/IJH97.04095 [doi]
PST - ppublish
SO  - Int J Hematol. 2005 Apr;81(3):235-41. doi: 10.1532/IJH97.04095.